General Dermatology

The app demonstrated high sensitivity (92.0%) and specificity (95.5%) in identifying skin changes through a controlled testing environment.

Efinaconazole demonstrated enhanced efficacy in treating nail fungal infections, thanks to its high penetration capability and low keratin binding.

Dermatology offers the power of choice, and it can be exactly what you make of it, writes our Fall Editor in Chief Raj Chovatiya, MD, PhD.

Join Dermatology Times in honoring World Mental Health Day on Oct 10, 2024.

The expanded dosage aims to provide healthcare providers with greater flexibility in treating larger or multiple areas affected by AK.

Researchers behind the review suggested that future research should prioritize large-scale trials to confirm abrocitinib's long-term safety and efficacy in various skin disorders.

Dermatology Times is looking back on the top stories in dermatology from the month of September.

Dermatology Times is recapping our top expert interviews from the month of September.

In recent years, there has been a noticeable rise in diagnoses of sexually transmitted infections, often which present with skin findings.

VYNE recently announced positive results for its novel oral small molecule BD2-selective BET inhibitor in a single-ascending dose clinical trial.

Learn more about the latest in dermatology from Sheila Fallon Friedlander, MD; Melodie Young, MSN, ANP-c; Raj Chovatiya, MD, PhD, MSCI; Julie Harper, MD; and Matthew Zirwas, MD.

Review cutaneous signs and symptoms of HAE that may enhance early diagnosis and treatment.

Lim discusses support for underserved communities, including dermatology training for Pacific Island Nations.

Elyse Love, MD, discusses the role of the program in supporting students with skin conditions the financial support and empowerment necessary for academic success.

Catch up on coverage from the fourth day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

Catch up on coverage from the third day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

Catch up on coverage from the second day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

During his session at Maui Derm NP+PA Fall, Hawkes emphasized the need for careful patient communication and shared his excitement for remibrutinib.

Catch up on coverage from the first day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

Researchers reported several factors and indicators that may predict early-stage systemic sclerosis among patients in Japan.

The subsequent MAD portion of the study has commenced dosing. Results are anticipated in Q4.

A recent reviewed showed that self-stigma in patients with skin disease is influenced by body image issues and social support.

New study results show promise in dupilumab for bullous pemphigoid, with 59% of patients avoiding disease relapse.

These positive data will support US regulatory submission by end of 2024.

Researchers stated the lack of reported clinical validation data raises concerns about their effectiveness and safety.